These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25150788)

  • 1. Does surveillance for hepatocellular carcinoma benefit patients with compensated cirrhosis?
    Yopp A; Waljee A; Singal AG
    Gastroenterology; 2014 Oct; 147(4):935-6. PubMed ID: 25150788
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: To PMID 24677195.
    Mourad A; Mathurin P; Deuffic-Burban S
    Gastroenterology; 2014 Oct; 147(4):936-7. PubMed ID: 25150789
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach.
    Mourad A; Deuffic-Burban S; Ganne-Carrié N; Renaut-Vantroys T; Rosa I; Bouvier AM; Launoy G; Cattan S; Louvet A; Dharancy S; Trinchet JC; Yazdanpanah Y; Mathurin P
    Hepatology; 2014 Apr; 59(4):1471-81. PubMed ID: 24677195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: first, eliminate the virus.
    Valla DC; Degos F
    J Hepatol; 2001 Apr; 34(4):606-9. PubMed ID: 11394663
    [No Abstract]   [Full Text] [Related]  

  • 5.  Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study.
    Hernaez R; El-Serag H
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):16-20. PubMed ID: 28051790
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients.
    Cucchetti A; D'Amico G; Trevisani F; Morelli MC; Vitale A; Pinna AD; Cescon M;
    Dig Liver Dis; 2018 Feb; 50(2):156-162. PubMed ID: 29102521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have?
    Giannini E; Testa R
    Gut; 2002 Oct; 51(4):611. PubMed ID: 12235093
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma.
    Kumada H
    Oncology; 2002; 62 Suppl 1():94-100. PubMed ID: 11868794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon and hepatocellular carcinoma.
    Koretz RL
    Lancet; 1996 Jan; 347(8995):194-5. PubMed ID: 8544565
    [No Abstract]   [Full Text] [Related]  

  • 12. What are the management issues for hepatitis C in dialysis patients?: natural history of hepatitis C in dialysis populations.
    Carrion AF; Martin P
    Semin Dial; 2014; 27(5):446-8. PubMed ID: 25204876
    [No Abstract]   [Full Text] [Related]  

  • 13. Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis.
    Ravi S; Axley P; Jones D; Kodali S; Simpson H; McGuire BM; Singal AK
    Gastroenterology; 2017 Mar; 152(4):911-912. PubMed ID: 28161225
    [No Abstract]   [Full Text] [Related]  

  • 14. A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma.
    Farinati F; Marino D; De Giorgio M; Trevisani F
    J Intern Med; 2004 Dec; 256(6):529-30; author reply 531. PubMed ID: 15554955
    [No Abstract]   [Full Text] [Related]  

  • 15. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
    Mantravadi S
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
    [No Abstract]   [Full Text] [Related]  

  • 16. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)].
    Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842
    [No Abstract]   [Full Text] [Related]  

  • 17. [Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?].
    Harada H; Iga D; Arisaka Y; Mitsuhashi Y; Kamitsukasa H; Yagura M; Endou H; Kawashima H
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):754-8. PubMed ID: 7563870
    [No Abstract]   [Full Text] [Related]  

  • 18. Infections and organ transplantation: new challenges for prevention and treatment of hepatitis C virus.
    Burra P; De Martin E
    Transplant Proc; 2011; 43(6):2455-6. PubMed ID: 21839292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
    Khokhar N; Niazi TK; Qureshi MO
    J Coll Physicians Surg Pak; 2013 Oct; 23(10):699-702. PubMed ID: 24112253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between hepatocellular carcinoma and hepatitis B and C virus.
    Kohli A
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):96-8. PubMed ID: 27057807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.